Author:
Slobodnick Anastasia,Shah Binita,Pillinger Michael H.,Krasnokutsky Svetlana
Funder
National Center for the Advancement of Translational Science
National Institutes of Health
Reference82 articles.
1. U.S. Food and Drug Administration. Drug safety information for healthcare professionals – information for healthcare professionals: new safety information for colchicine (marketed as Colcrys). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm. Accessed May 28, 2014.
2. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study;Terkeltaub;Arthritis Rheum,2010
3. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials;Wortmann;Clin Ther,2010
4. Intravenous colchicine in the treatment of acute pseudogout;Tabatabai;Arthritis Rheum,1980
5. Colchicine for familial Mediterranean fever;Goldfinger;N Engl J Med,1972
Cited by
248 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献